Dr. Denis Bauer is the team leader of the transformational bioinformatics team in CSIRO’s ehealth program. She has a PhD in Bioinformatics from the University of Queensland and held Post-doctoral appointments in biological machine learning at the Institute for Molecular Bioscience and in genetics at the Queensland Brain institute. Her expertise is in computational genome engineering and BigData compute systems. She is involved in national and international initiatives tasked to include genomic information into medical practice, funded with $200M. She has 31 peer-reviewed publications (14 as first or senior author) with 7 in journals of IF>8 (e.g. Nat Genet.) and H-index 11. To date she has attracted more than $6.5Million in funding as Chief investigator.
University of California
Adam L. Boxer, MD, PhD is Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF). He directs UCSF’s Neurosciences Clinical Research Unit and the Alzheimer’s Disease and Frontotemporal Degeneration (FTD) Clinical Trials Program at the UCSF Memory and Aging Center. Dr Boxer’s research is focused on developing new treatments and biomarkers for neurodegenerative diseases, particularly those involving tau and TDP-43. He is the Principal Investigator of the Advancing Research and Treatment for FTLD (ARTFL) Rare Disease Clinical Research Consortium, a collaborative project funded by the National Institutes of Health to create an 18 center North American research network to support the development of new therapies for FTLD. He also leads the Four Repeat Tauopathy Neuroimaging Initiative (4RTNI), a multicenter, longitudinal tau PET and biomarker study focused on PSP and CBD. He has been the PI for a variety of multicenter, randomized, placebo controlled clinical trials in FTLD spectrum disorders, including memantine for FTLD, davunetide for PSP, TPI-287 for primary and secondary tauopathies, and salsalate for PSP. He is lead principle investigator for an international Phase 2 clinical trial of the tau monoclonal antibody, BIIB092, for PSP. He chairs the FTLD Treatment Study Group (FTSG), an academic-industry collaborative group working to speed the development of new therapies for FTLD.
Gaël Chételat (PhD, HDR; www.gael-chetelat.fr) is Director of Research at Inserm. She is responsible of a research team named Multimodal Neuroimaging and Lifestyle in Ageing and Dementia. She has published more than 120 articles on neuroimaging in ageing and dementia. Her work is devoted to the understanding of the mechanisms underlying ageing and dementia processes and the lifestyle factors that could prevent or delay age-associated disorders. The specificity of her team is to conduct studies combining complementary neuroimaging modalities, including structural and functional MRI with PET using different radiotracers, and to develop innovative multimodal neuroimaging approaches to disentangle complex mechanisms of diseases or cognitive processes. Her research team is also interested in promoting healthy ageing and wellbeing through non-pharmaceutical interventions. In particular, Gaël Chételat is coordinating an H2020 European grant (www.silversantestudy.eu, PHC22, 2015-2020) that will investigate the impact of English learning and meditation training on mental health and well-being in ageing populations.
University of California
Dr. Huang received his M.D. from the National Taiwan University and Ph.D. in Molecular Biology from Cornell University Graduate School of Medical Sciences. Since 2009, Dr. Huang has been a full professor in the Dept of Pathology at the University of California San Francisco (UCSF). Dr. Huang is also the Director of the newly established Division of Neuropathology Research at the Weill Institute for Neurosciences at UCSF. Dr. Huang’s research focuses on the molecular and cellular mechanisms of neural circuit development and degeneration in the human brain. Recent studies from Dr. Huang’s laboratory have uncovered the extensive migration of young neurons in the postnatal human brain and how these neurons may contribute to the neural circuit and cognitive development in the human brain. In addition, Dr. Huang and his colleagues investigate the mechanisms and pathogenesis of neurodegenerative diseases, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Dr. Huang received several distinguished honors, including the Presidential Early Career Award for Scientists and Engineers (PECASE)(2000 – 2005), the Independent Scientist Award (2002 – 2007), the Mid-career Investigator Award (2009 – 2014), Chair of Gordon Research Conference on Molecular and Cellular Neurobiology (2014), the DeArmond Lecture (2016) and the Stowell Lecture (2017). Dr. Huang has authored or co-authored more than 100 papers. His recent study on the role of progranulin deficiency in microglial activation and circuit-specific synaptic pruning has been cited as the “Notable Advances in 2016” by Nature Medicine.
University of New South Wales
Lars Ittner is a Professor at the University of New South Wales (UNSW) and a Senior Principal Research Fellow at Neuroscience Research Australia (NeuRA). Lars graduated in Medicine from the University of Ulm in Germany, and received his M.D. from the University of Zurich in Switzerland in 2002, where he then studied neuronal stem cells and signalling pathways. In 2005, he moved to Australia to focus his work on basic pathomechanisms underlying neurodegenerative diseases. In 2013, he was appointed to the University of New South Wales in Sydney to head the Dementia Research and the Transgenic Animal Units. He has made major contributions to the understanding of fundamental pathomechanisms in Alzheimer’s disease and frontotemporal dementia and identified novel targets for drug development in these diseases. Lars has published over 100 papers with more than 7000 citations, including in leading scientific journals, such as Science, Cell and Nature Medicine. Lars is the recipient of the ASBMB Merck Research Medal 2017 and a chief investigator on the NHMRC Program Grant ForeFront, investigating frontotemporal dementia and motor neurodegenerative syndromes.
University of Sydney
Matthew C Kiernan PhD, DSc FRACP FAHMS
Professor Matthew Kiernan is the Co-Director, Brain and Mind Centre at the University of Sydney. His role is to foster multidisciplinary research across the clinical neurosciences, to improve research outcomes and facilitate the translation of research innovations directly into clinical practice for the benefit of patients and the community.
Professor Matthew Kiernan is the Bushell Chair of Neurology, responsible for the discipline of neurology at the University of Sydney. He is a Professor of Neurology at the Royal Prince Alfred Hospital, President of the Australian and New Zealand Association of Neurologists and Editor-in-Chief of the Journal of Neurology, Neurosurgery & Psychaitry (BMJ Publishers, UK).
Medical University of Vienna
After receiving MD degree in Budapest, Hungary, Dr Kovacs obtained qualification in neurology (1998) and neuropathology (2003) and PhD in Neuroscience (2002). Between 2004 and 2007 he was the Head of the Department of Neuropathology, National Institute of Psychiatry and Neurology, Budapest, Hungary. Since 2007 he works at the Medical University of Vienna where he habilitated in 2010. He is the leader of the Neurodegenerative disease research group at the Institute of Neurology, Medical University of Vienna, the Hungarian (2004) and the Austrian (2011) Reference Center for Human Prion diseases. His research visits included Edinburgh, UK (J.W. Ironside), Vienna (H. Budka), Indianapolis (B. Ghetti), and Philadelphia (J.Q. Trojanowski and V.M-Y. Lee). His achievements include characterization and pathogenic elucidation of peculiar types of neurological diseases, like frontotemporal dementia with tau-positive globular glial inclusions, a tauopathy affecting elderly individuals and studies on human prion diseases. He coordinated an international consensus on ageing-related tau-astrogliopathy (ARTAG). His group participated in the EU Project BrainNet Europe II focusing on brain banking. He coordinated an FP7 EU Project (DEVELAGE) examining brain ageing and brain development. His scientific oeuvre includes 237 Publications in Web of Science and H-Index of 45; he edited two books on Neuropathology and contributed chapters to 9 further books. He is in the Editorial Board of Acta Neuropathologica, Neuropathology and Applied Neurobiology, and Basal Ganglia. His group focuses on molecular pathological patterns (particularly tau) and genotypes associated with clinical syndromes; body-fluid biomarkers; and comparative studies of brain ageing and development.
University of Manchester
I obtained my PhD from York University and then worked at the MRC Cognition and Brain Sciences Unit (Cambridge). I moved from there to the University of Bristol, Department of Experimental Psychology, as a Lecturer. I came to Manchester in 2001 as Professor of Cognitive Neuroscience within the School of Psychological Sciences. I am also Associate Vice-President (Research) and Director of the Manchester Doctoral College at the University. I am an Action Editor for Neuropsychological Rehabilitation and on the editorial boards for Cognitive Neuropsychology, Memory, International Journal of Language & Communication Disorders, Alzheimer's Research & Therapy, Psychologia, and Neurocase. I was the President of The British Neuropsychological Society (2010-12) and the Vice-Chair for the British Aphasiology Society (2000-2005). I was made a Fellow (hons) of the Royal College of Speech and Language Therapists in 2003, Fellow of the British Psychological Society in 2012 and an Honorary Research Professor of the University of Málaga in 2014. I am also a Senior Investigator Emeritus for the NIHR. I was awarded the BPS President's Award in 2015, the Barbara Newcombe (mid-career) Prize by the British Neuropsychological Society in 2016, and the Mid-Career Award by the British Association for Cognitive Neuroscience in 2016. I am currently the chair of the EU Human Brain Project Stakeholder Board (the principal oversight committee).
Mayo Clinic Jacksonville
Dr. Rademakers is consultant and Professor of Neuroscience at Mayo Clinic in Florida and is recognized as the Mildred A. and Henry Uihlein II Professor of Medical Research. Her research is focused on the molecular genetics analyses of neurodegenerative diseases, with a special interest in frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS) and early-onset Alzheimer’s Disease (AD). Her research program aims to provide new insights into disease pathogenesis and to identify novel targets for therapy through the discovery and subsequent study of novel disease genes. Dr. Rademakers has been at the forefront of neurodegenerative disease research since playing a critical role in the discovery of progranulin (GRN) as the first causal gene implicated in FTD with TDP-43 pathology (FTLD-TDP). In 2011, her laboratory made the discovery that C9ORF72 repeat expansions were the long sought-after cause of ALS and FTD linked to chromosome 9p. Dr. Rademakers has published over 275 peer‐reviewed original articles and reviews and her research is supported by multiple NIH grants. She is President-Elect of the International Society for Frontotemporal Dementias and is a member of the Medical Advisory Council of the Association for Frontotemporal Degeneration. She has received the Paolo Gontijo Medicine Award and the Sheila Essey Award for ALS Research from the ALS Association in partnership with the American Academy of Neurology. She is also the recipient of the 2016 Potamkin Prize for Research in Pick’s, Alzheimer’s and Related Disorders of the American Academy of Neurology.
University of California
Dr. Seeley is a behavioral neurologist and neuroscientist at the University of California, San Francisco, where he is a Professor of Neurology and Pathology and Director of the Neurodegenerative Disease Brain Bank. Dr. Seeley and his coworkers investigate the anatomical onset and progression of neurodegenerative disease, with a focus on frontotemporal dementia. Their research blends neuroanatomy, brain mapping, and neuropathology with molecular-genetic analyses, with the goal of accelerating drug discovery by clarifying selective vulnerability mechanisms and by developing network-based neuroimaging biomarkers for monitoring disease progression. Dr. Seeley is a fellow of the American Academy for the Advancement of Science and the American Society for Clinical Investigation, and his work was recognized in 2011 with a Fellowship from the John D. and Catherine T. MacArthur Foundation.
Duke-National University of Singapore
Dr. Juan (Helen) Zhou is an Assistant professor at the Centre for Cognitive Neuroscience, Neuroscience and Behavioral Disorders Program at Duke-National University of Singapore Medical School, Singapore. She is also a principal investigator at the Clinical Imaging Research Center, A*STAR and National University of Singapore. Prior to joining Duke-NUS in 2011, Helen was an associate research scientist in the Child Study Centre, New York University. She did a two-year post-doctoral fellowship at the Memory and Aging Centre, Department of Neurology, University of California, San Francisco, from 2008 to 2010. Helen received her Bachelor degree in Computer Science in 2003 and Ph.D. in Neuroimaging in 2007 from Nanyang Technological University, Singapore. She is the recipient of the undergraduate scholarship from Ministry of Education, Singapore (1998-2003) and the nominee for Lee Kuan Yew Gold Medal and the Institution of Engineers Singapore Gold Medal, Singapore in 2004. Helen received research funding from National Medical Research Council, Biomedical Research Council and National Research Foundation, Singapore as well as the Royal Society, UK. Her research focuses on the network-based vulnerability hypothesis in disease. Her lab studies the human neural bases of cognitive functions and the associated vulnerability patterns in aging and neuropsychiatric disorders using multimodal neuroimaging methods (MRI/fMRI/DTI/EEG) and psychophysical techniques. She is interested in the large-scale brain structural and functional networks in healthy developing and ageing brain and symptoms-related changes in diseases such as neurodegenerative disorders and psychosis. Statistical and computational methods are developed to analyze and fuse longitudinal multimodal neuroimaging, behavior, and clinical data to 1) detect early brain network changes in preclinical or prodromal disease stages; 2) understand network dynamics and disease mechanisms; 3) evaluate intervention efficacy on brain networks. She serves on the OHBM Program Committee and Society of Neuroscience Singapore Chapter committee.